The Emerging FGF21 Axis in Thyroid Eye Disease: Metabolic–Immune Crosstalk and Therapeutic Perspectives

Authors

  • Michael Edwar, Hoda G. Bakr, Mostafa Ahmed Abd Elaziz, Abdalla M. Abdelrahman, Tahia Mohamed Ahmed Mohamed, Ahmed Atef Zaki Arafa Author

DOI:

https://doi.org/10.48047/n0mwx095

Keywords:

fibroblast growth factor 21, thyroid eye disease, orbital fibroblasts, immunometabolism

Abstract

Background: Thyroid eye disease (TED) is an organ-specific autoimmune disorder characterized by orbital inflammation, fibroblast 
activation, extracellular matrix expansion, adipogenesis, extraocular muscle enlargement, and progressive tissue remodeling. Although thyrotropin receptor and insulin-like growth factor-1 receptor signaling remain central to current models of TED pathogenesis, increasing evidence indicates that metabolic stress, oxidative injury, mitochondrial dysfunction

Downloads

Download data is not yet available.

References

Wiersinga WM, Eckstein AK, Žarković M. Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2025;13(7):600-614. doi:10.1016/S2213-8587(25)00066-X.

Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 European Group on Graves' Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021;185(4):G43-G67. doi:10.1530/EJE-21-0479.

Downloads

Published

2024-11-20

How to Cite

The Emerging FGF21 Axis in Thyroid Eye Disease: Metabolic–Immune Crosstalk and Therapeutic Perspectives (Michael Edwar, Hoda G. Bakr, Mostafa Ahmed Abd Elaziz, Abdalla M. Abdelrahman, Tahia Mohamed Ahmed Mohamed, Ahmed Atef Zaki Arafa , Trans.). (2024). Cuestiones De Fisioterapia, 53(03), 8489-8497. https://doi.org/10.48047/n0mwx095